Abstract
Background Among common cancers in women, ovarian cancer has the lowest incidence; however, mortality rates are more than other gynecological cancers due to the lack of specific symptoms during early stages and absence of diagnostic markers. Golgi integral membrane protein 4 (GOLIM4) is a member of transporter complex which is located to the cis/medial of Golgi, and its role in tumor is unknown. In this study we aimed to assess the expression of Golim4 (GPP130) in epithelial ovarian cancer (EOC) patients.
Methods The expression levels of Golim4 in 58 malignant EOC specimens and 11 benign and normal control tissues were determined by real-time RT-PCR. Clinicopathological characteristics were analyzed. Non-parametric survival analysis was estimated by using Kaplan-Meier and log-rank test. Parametric survival analysis was evaluated through multivariate Cox regression analysis and generalized Gamma survival model.
Result Our findings showed that Golim4 was significantly down-regulated in Serous Papillary type of EOC tissue specimens than in non-cancerous tissues (P<0.001); however; the expression of Golim4 in total EOC tissue specimens revealed non-significant up-regulation. Kaplan-Meier analysis and log-rank test have suggested that EOC patients with low Golim4 expression have shorter overall survival when compared with patients with other expression groups (log-rank test P<0.05). Semi-parametric Cox proportional hazards model indicated that the status of Golim4 were independent predictor of overall survival in patients with EOC. Correlation analysis has been done by Spearman Rank correlation coefficient.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Tarbiat Modares university gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
